BRGX · XBRL financial data
Bioregenx financial statements, every quarter
The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (BRGX's year ends in late December)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0* | 1 | 1 | 1 | 0* | 1 | 0 | 1 | 0* | 0 |
| Cost of revenue | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 |
| Gross profit | 1 | 1 | — | 0 | 0 | 0 | — | 0 | 0 | 0 | — | 0 |
| Research and development | 0 | 0 | 0* | 0 | 0 | 0 | (0)* | 0 | 0 | 0 | 0* | — |
| Selling, general and administrative | 1 | 3 | 0* | 3 | 1 | 0 | 2* | 1 | 0 | 0 | 1* | 0 |
| Total operating expenses | 0 | 0 | 0* | 3 | 2 | 1 | 19* | 1 | 0 | 0 | 1* | 0 |
| Operating income (loss) | (0) | (0) | (0)* | (3) | (1) | (0) | (18)* | (0) | (0) | (0) | (1)* | (0) |
| Interest expense | 0 | 0 | 0* | 0 | 0 | 0 | (0)* | 0 | 0 | 0 | 0* | 0 |
| Income tax expense (benefit) | 0 | 0 | 0* | 0 | — | — | — | — | — | — | — | — |
| Net income (loss) | (0) | (0) | (0)* | (3) | (1) | (0) | (18)* | (0) | (0) | (0) | (1)* | (0) |
| Earnings per share, basic USD per share | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | (0.02)* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 |
| Earnings per share, diluted USD per share | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | (0.02)* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 |
| Weighted average shares, basic millions of shares | 270 | 270 | 291* | 768 | 957 | 957 | 1,076* | 957 | 959 | 961 | 962* | 969 |
| Weighted average shares, diluted millions of shares | 270 | 270 | 291* | 768 | 957 | 957 | 1,076* | 957 | 959 | 961 | 962* | 969 |
Balance sheet
CSVFiscal quarters (BRGX's year ends in late December)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts receivable | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property and equipment, net | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | — | — | 0 | 7 | 7 | 7 | — | — | — | — | — | — |
| Total assets | 0 | 0 | 0 | 19 | 18 | 17 | 1 | 0 | 1 | 1 | 0 | 0 |
| Accounts payable | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Accrued liabilities | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Current portion of long-term debt | 0 | 0 | 0 | — | — | — | 1 | — | — | — | 1 | — |
| Total current liabilities | 0 | 0 | 0 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Long-term debt | 0 | 0 | 0 | — | — | — | 0 | — | — | — | 0 | — |
| Total liabilities | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Accumulated deficit | (3) | (3) | (4) | (16) | (17) | (17) | (36) | (36) | (36) | (36) | (37) | (37) |
| Total stockholders' equity | (0) | (0) | (0) | 15 | 14 | 14 | (3) | (4) | (4) | (4) | (5) | (5) |
| Total liabilities and equity | 0 | 0 | 0 | 19 | 18 | 17 | 1 | 0 | 1 | 1 | 0 | 0 |
| Common shares outstanding (cover page) millions of shares | 277 | 277 | 957 | 957 | 957 | 957 | 957 | 960 | 961 | 962 | 969 | 972 |
Cash flows
CSVFiscal quarters (BRGX's year ends in late December)
| In millions of dollars | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (0) | (0) | (0)* | (3) | (1) | (0) | (18)* | (0) | (0) | (0) | (1)* | (0) |
| Stock-based compensation | — | — | 2* | 2 | 0* | (0)* | 1* | 0 | 0* | 0* | 0* | 0 |
| Depreciation and amortization | 0 | 0 | (0)* | 1 | 0 | 0 | 2* | 0 | — | — | year only | 0 |
| Net cash from operating activities | 0* | (0)* | (0)* | (0) | (0)* | (0)* | (0)* | 0 | 0* | (0)* | 0* | 0 |
| Purchases of property and equipment | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | — |
| Net cash from investing activities | 0* | 0* | 0* | (0) | 0* | 0* | 0* | 0 | (0)* | (0)* | (0)* | — |
| Proceeds from issuing common stock | 0* | 0* | 1* | 0 | 0* | 0* | 0* | — | — | — | — | — |
| Net cash from financing activities | 0* | 0* | 0* | 0 | 0* | 0* | (0)* | (0) | 0* | 0* | (0)* | (0) |
| Net change in cash | (0)* | (0)* | 0* | (0) | (0)* | 0* | (0)* | 0 | (0)* | 0* | 0* | (0) |
Compare with peers
SIC 7370 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 7370 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Bioregenx | 0 | 0.4 | 0 | 971.6M | — | 10-QMar 31, 2026 |
| Auddia | 9.6 | 0 | (2.5)* | 5.8M | 3.8 quarters | 10-QJun 30, 2026 |
| Powerdyne International | 0.1 | 0.3 | (0.1)* | 2.0B | 0.9 quarters | 10-QJun 30, 2026 |
| My Size | 0.5 | 3.1 | 0* | 728,482 | — | 10-QJun 30, 2026 |
| ZW Data Action Technologies | 0.6 | 0.7 | (0.1)* | 3.7M | 5.7 quarters | 10-QJun 30, 2026 |
| Super League Enterprise | 1.1 | not reported | (2.2)* | 1.7M | 3.0 quarters | 10-QJun 30, 2026 |
| Versus Systems | 1.4 | 0 | (0.5)* | 6.2M | 2.9 quarters | 10-QJun 30, 2026 |
| Onfolio Holdings | 0.3 | 1.5 | (0.6)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Techlott | 0.5 | not reported | (0.3)* | 890.7M | 1.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.